GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference. Details are as follows:
| Conference: | Guggenheim SMID Cap Biotech Conference | |
| Date/Time: | Wednesday, February 5, 2025, at 9:30 a.m. EST | |
The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
HOUSTON, April 11, 2025 /PRNewswire/ -- Nauticus Robotics, Inc. ("Nauticus" or "Company") (NASDAQ: KITT) today…
NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation…
PARSIPPANY, N.J., April 11, 2025 /PRNewswire/ -- Diagnostica Stago, Inc., a global leader in hemostasis…
The Company Expects the Continued Sale of OPKO-Branded Products in China but is Pausing Activities…
BRIDGEWATER, N.J., April 11, 2025 /PRNewswire/ -- Hamamatsu Photonics, a global leader in whole slide…
NASHVILLE, Tenn., April 11, 2025 /PRNewswire/ -- Entering its 15th year, ProviderTrust continues to lead…